Insider Buying: SIGA Technologies, Inc. (OTCMKTS:SIGA) Director Buys $86,800.00 in Stock

SIGA Technologies, Inc. (OTCMKTS:SIGA) Director Paul G. Savas bought 20,000 shares of the stock in a transaction on Monday, December 9th. The stock was bought at an average price of $4.34 per share, for a total transaction of $86,800.00.

Shares of SIGA stock opened at $4.55 on Friday. The business’s 50 day moving average is $5.12 and its two-hundred day moving average is $5.35. SIGA Technologies, Inc. has a twelve month low of $4.28 and a twelve month high of $8.09.

SIGA Technologies (OTCMKTS:SIGA) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.03) earnings per share for the quarter. The business had revenue of $8.11 million during the quarter.

Several hedge funds have recently made changes to their positions in the business. Millennium Management LLC purchased a new position in shares of SIGA Technologies in the 3rd quarter valued at approximately $78,000. Zebra Capital Management LLC grew its stake in shares of SIGA Technologies by 312.6% in the 3rd quarter. Zebra Capital Management LLC now owns 230,630 shares of the biotechnology company’s stock valued at $1,181,000 after purchasing an additional 174,739 shares during the last quarter. State Street Corp grew its stake in shares of SIGA Technologies by 1.2% in the 3rd quarter. State Street Corp now owns 1,000,539 shares of the biotechnology company’s stock valued at $5,123,000 after purchasing an additional 11,924 shares during the last quarter. BBVA USA Bancshares Inc. purchased a new position in shares of SIGA Technologies in the 3rd quarter valued at approximately $67,840,000. Finally, Investment Management of Virginia LLC purchased a new position in shares of SIGA Technologies in the 3rd quarter valued at approximately $52,000. Institutional investors own 6.66% of the company’s stock.

SIGA Technologies Company Profile

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Featured Story: What is dollar cost averaging (DCA)?

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.